Friday's after hours session: top gainers and losers After the closing bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Liquidia Scores FDA Nod For Lung Disease Drug Yutrepia, Faces Legal Challenge Liquidia gains FDA approval for Yutrepia to treat PAH and PH-ILD, with funding in place despite ongoing patent litigation with United Therapeutics
Liquidia Retail Buzz Surges After BofA Raises Price Target to $25 On Yutrepia FDA Nod The company’s proprietary dry-powder formulation, supported by Phase 3 data, is viewed as a promising alternative to United Therapeutics’ Tyvaso, though legal challenges remain pending.
Jim Cramer Praises PayPal CEO Alex Chriss: 'Financial Techs Have Come Back In Style' PayPal CEO Alex Chriss "is a very good manager," Cramer said. Plus: AST SpaceMobile, Flutter Entertainment and more.
